|
1
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al
National Cancer Institute of Canada Clinical Trials Group:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al Groupe Tumeurs Digestives of Unicancer;
PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang-Gillam A, Li CP, Bodoky G, Dean A,
Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, et
al NAPOLI-1 Study Group: Nanoliposomal irinotecan with fluorouracil
and folinic acid in metastatic pancreatic cancer after previous
gemcitabine-based therapy (NAPOLI-1): A global, randomised,
open-label, phase 3 trial. Lancet. 387:545–557. 2016. View Article : Google Scholar
|
|
7
|
Kozak G, Blanco FF and Brody JR: Novel
targets in pancreatic cancer research. Semin Oncol. 42:177–187.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Macgregor-Das AM and Iacobuzio-Donahue CA:
Molecular pathways in pancreatic carcinogenesis. J Surg Oncol.
107:8–14. 2013. View Article : Google Scholar :
|
|
9
|
Thorpe LM, Yuzugullu H and Zhao JJ: PI3K
in cancer: Divergent roles of isoforms, modes of activation and
therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar :
|
|
10
|
Ocana A, Vera-Badillo F, Al-Mubarak M,
Templeton AJ, Corrales-Sanchez V, Diez-Gonzalez L, Cuenca-Lopez MD,
Seruga B, Pandiella A and Amir E: Activation of the PI3K/mTOR/AKT
pathway and survival in solid tumors: Systematic review and
meta-analysis. PLoS One. 9:e952192014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nitulescu GM, Margina D, Juzenas P, Peng
Q, Olaru OT, Saloustros E, Fenga C, Spandidos DA, Libra M and
Tsatsakis AM: Akt inhibitors in cancer treatment: The long journey
from drug discovery to clinical use (Review). Int J Oncol.
48:869–885. 2016.
|
|
12
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ruggeri BA, Huang L, Wood M, Cheng JQ and
Testa JR: Amplification and overexpression of the AKT2 oncogene in
a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog.
21:81–86. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamamoto S, Tomita Y, Hoshida Y, Morooka
T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H,
et al: Prognostic significance of activated Akt expression in
pancreatic ductal adenocarcinoma. Clin Cancer Res. 10:2846–2850.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dobashi Y, Kimura M, Matsubara H, Endo S,
Inazawa J and Ooi A: Molecular alterations in AKT and its protein
activation in human lung carcinomas. Hum Pathol. 43:2229–2240.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rychahou PG, Kang J, Gulhati P, Doan HQ,
Chen LA, Xiao SY, Chung DH and Evers BM: Akt2 overexpression plays
a critical role in the establishment of colorectal cancer
metastasis. Proc Natl Acad Sci USA. 105:20315–20320. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakayama K, Nakayama N, Kurman RJ, Cope L,
Pohl G, Samuels Y, Velculescu VE, Wang TL and Shih IeM: Sequence
mutations and amplification of PIK3CA and AKT2 genes in purified
ovarian serous neoplasms. Cancer Biol Ther. 5:779–785. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bacus SS, Altomare DA, Lyass L, Chin DM,
Farrell MP, Gurova K, Gudkov A and Testa JR: AKT2 is frequently
upregulated in HER-2/neu-positive breast cancers and may contribute
to tumor aggressiveness by enhancing cell survival. Oncogene.
21:3532–3540. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bellacosa A, de Feo D, Godwin AK, Bell DW,
Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, et
al: Molecular alterations of the AKT2 oncogene in ovarian and
breast carcinomas. Int J Cancer. 64:280–285. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Edling CE, Selvaggi F, Buus R, Maffucci T,
Di Sebastiano P, Friess H, Innocenti P, Kocher HM and Falasca M:
Key role of phosphoinositide 3-kinase class IB in pancreatic
cancer. Clin Cancer Res. 16:4928–4937. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wong MH, Xue A, Julovi SM, Pavlakis N,
Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC and Smith RC:
Cotargeting of epidermal growth factor receptor and PI3K overcomes
PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Clin Cancer Res. 20:4047–4058. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
De Velasco MA, Tanaka M, Yamamoto Y,
Hatanaka Y, Koike H, Nishio K, Yoshikawa K and Uemura H: Androgen
deprivation induces phenotypic plasticity and promotes resistance
to molecular targeted therapy in a PTEN-deficient mouse model of
prostate cancer. Carcinogenesis. 35:2142–2153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arao T, Ueshima K, Matsumoto K, Nagai T,
Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H, et
al: FGF3/FGF4 amplification and multiple lung metastases in
responders to sorafenib in hepatocellular carcinoma. Hepatology.
57:1407–1415. 2013. View Article : Google Scholar
|
|
24
|
Togashi Y, Kogita A, Sakamoto H, Hayashi
H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano
M, et al: Activin signal promotes cancer progression and is
involved in cachexia in a subset of pancreatic cancer. Cancer Lett.
356(2 Pt B): 819–827. 2015. View Article : Google Scholar
|
|
25
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
da Cunha Santos G, Dhani N, Tu D, Chin K,
Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ and Tsao
MS: Molecular predictors of outcome in a phase 3 study of
gemcitabine and erlotinib therapy in patients with advanced
pancreatic cancer: National Cancer Institute of Canada Clinical
Trials Group Study PA.3. Cancer. 116:5599–5607. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tzeng CW, Frolov A, Frolova N, Jhala NC,
Howard JH, Buchsbaum DJ, Vickers SM, Heslin MJ and Arnoletti JP:
Epidermal growth factor receptor (EGFR) is highly conserved in
pancreatic cancer. Surgery. 141:464–469. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sartore-Bianchi A, Martini M, Molinari F,
Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P,
De Dosso S, Mazzucchelli L, et al: PIK3CA mutations in colorectal
cancer are associated with clinical resistance to EGFR-targeted
monoclonal antibodies. Cancer Res. 69:1851–1857. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
De Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS,
and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy
in chemotherapy-refractory metastatic colorectal cancer: A
retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sos ML, Koker M, Weir BA, Heynck S,
Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P,
et al: PTEN loss contributes to erlotinib resistance in EGFR-mutant
lung cancer by activation of Akt and EGFR. Cancer Res.
69:3256–3261. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jeannot V, Busser B, Brambilla E, Wislez
M, Robin B, Cadranel J, Coll JL and Hurbin A: The PI3K/AKT pathway
promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by
a deacetylase-dependent mechanism. Int J Cancer. 134:2560–2571.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tamm EP, Bhosale PR and Lee JH: Pancreatic
ductal adenocarcinoma: Ultrasound, computed tomography, and
magnetic resonance imaging features. Semin Ultrasound CT MR.
28:330–338. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kitano M, Kudo M, Yamao K, Takagi T,
Sakamoto H, Komaki T, Kamata K, Imai H, Chiba Y, Okada M, et al:
Characterization of small solid tumors in the pancreas: The value
of contrast-enhanced harmonic endoscopic ultrasonography. Am J
Gastroenterol. 107:303–310. 2012. View Article : Google Scholar
|
|
38
|
Diaz LA Jr and Bardelli A: Liquid
biopsies: Genotyping circulating tumor DNA. J Clin Oncol.
32:579–586. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Heitzer E, Ulz P and Geigl JB: Circulating
tumor DNA as a liquid biopsy for cancer. Clin Chem. 61:112–123.
2015. View Article : Google Scholar
|
|
40
|
Gridelli C, Peters S, Sgambato A, Casaluce
F, Adjei AA and Ciardiello F: ALK inhibitors in the treatment of
advanced NSCLC. Cancer Treat Rev. 40:300–306. 2014. View Article : Google Scholar
|
|
41
|
Roengvoraphoj M, Tsongalis GJ, Dragnev KH
and Rigas JR: Epidermal growth factor receptor tyrosine kinase
inhibitors as initial therapy for non-small cell lung cancer: Focus
on epidermal growth factor receptor mutation testing and
mutation-positive patients. Cancer Treat Rev. 39:839–850. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang JC, Sequist LV, Geater SL, Tsai CM,
Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, et al:
Clinical activity of afatinib in patients with advanced
non-small-cell lung cancer harbouring uncommon EGFR mutations: A
combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung
6. Lancet Oncol. 16:830–838. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi
H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, et
al: EGFR exon 18 mutations in lung cancer: Molecular predictors of
augmented sensitivity to afatinib or neratinib as compared with
first- or third-generation TKIs. Clin Cancer Res. 21:5305–5313.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Banno E, Togashi Y, Nakamura Y, Chiba M,
Kobayashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita
Y, et al: Sensitivities to various epidermal growth factor
receptor-tyrosine kinase inhibitors of uncommon epidermal growth
factor receptor mutations L861Q and S768I: What is the optimal
epidermal growth factor receptor-tyrosine kinase inhibitor? Cancer
Sci. 107:1134–1140. 2016. View Article : Google Scholar : PubMed/NCBI
|
